e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Idiopathic pulmonary fibrosis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world
C. Sugimoto (Sakai, Osaka, Japan)
Source:
International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Session:
Idiopathic pulmonary fibrosis: from the bench to the bedside
Session type:
Poster Discussion
Number:
4878
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Sugimoto (Sakai, Osaka, Japan). Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world. 4878
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017
Year: 2017
A prosprective study on the safety, tolerability and efficacy of pirfinidone in the treatment of idiopathic pulmonary fibrosis and fibrotic NSIP
Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis
Year: 2012
Team support with pharmacists improved tolerability of antifibrotic agents for pulmonary fibrosis.
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Results of antifibrotic drugs in the treatment of idiopathic pulmonary fibrosis. A real life study.
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1382-1392
Year: 2015
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation
Source: International Congress 2018 – Moving lung transplantation forward
Year: 2018
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2006; 28: Suppl. 50, 767s
Year: 2006
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Source: Eur Respir J, 52 (2) 1800230; 10.1183/13993003.00230-2018
Year: 2018
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
Year: 2018
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF)
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept